ReviewPaediatric drugs2018
Comparative Effectiveness Research in Pediatric Respiratory Disease: Promise and Pitfalls.
Kathleen J Ramos, Ranjani Somayaji, David P Nichols, Christopher H Goss
Abstract readReview
In one paragraphReview in Paediatric drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
4 authors.
Kathleen J RamosDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA, USA.
Ranjani SomayajiDepartment of Medicine, University of Calgary, Calgary, AB, Canada.
David P NicholsDivision of Pulmonary Medicine, Department of Pediatrics, Seattle Children's Hospital, Seattle, WA, USA.
Christopher H GossDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA, USA. goss@u.washington.edu.
Funding
Transform Dissemination and Implementation Science in CTSA ProgramsUL1TR002319 · NCATS · UNIVERSITY OF WASHINGTON · PI John K. Amory · 2017 to 2026
$100.0MTranslational Research Center to Expedite Novel Therapies in Cystic FibrosisP30DK089507 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI Christopher Hooper Goss · 2010 to 2026
$21.4MProof of Principle Evaluation of IV Gallium Nitrate in Patients with CFUM1HL119073 · NHLBI · UNIVERSITY OF WASHINGTON · PI GOSS, CHRISTOPHER HOOPER, SINGH, PRADEEP K · 2013 to 2017
$4.8MEarly Intervention in Pulmonary Exacerbation in CFR01HL103965 · NHLBI · UNIVERSITY OF WASHINGTON · PI GOSS, CHRISTOPHER HOOPER, LECHTZIN, NOAH · 2010 to 2014
$3.8MOPTIMIZE - DCCU01HL114589 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI HAMBLETT, NICOLE MAYER · 2013 to 2017
$3.3MInvestigating treatment resistance mechanisms in chronic bacterial infectionsR01AI101307 · NIAID · UNIVERSITY OF WASHINGTON · PI BRUCE, JAMES EDWARD, MANOIL, COLIN · 2012 to 2016
$2.9MA prospective trial of oral azithromycin when added to inhaled tobramycin in CFR01HL124053 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI NICHOLS, DAVID PAUL · 2015 to 2019
$2.8MRegulation of host inflammatory responses and outcome in melioidosis by TLR5R01HL113382 · NHLBI · UNIVERSITY OF WASHINGTON · PI WEST, TIMOTHY EOIN · 2012 to 2016
$2.6MPhase 2 Study of Intravenous Gallium Nitrate in the Treatment of Cystic FibrosisR01FD003704 · FDA · UNIVERSITY OF WASHINGTON · PI GOSS, CHRISTOPHER HOOPER · 2009 to 2018
$2.0MPredicting survival and planning for lung transplantation in severe cystic fibrosisK23HL138154 · NHLBI · UNIVERSITY OF WASHINGTON · PI RAMOS, KATHLEEN JESSICA · 2017 to 2021
$947kCanadian Institutes of Health Research 201511MFE-359236-270022Cystic Fibrosis Canada CFCID3237Cystic Fibrosis Foundation Therapeutics RAMOS16A0FDA HHS R01 FD003704National Heart, Lung, and Blood Institute R01HL103965National Heart, Lung, and Blood Institute R01HL113382National Heart, Lung, and Blood Institute R01HL124053National Heart, Lung, and Blood Institute U01HL114589National Heart, Lung, and Blood Institute UM1HL119073National Institute of Diabetes and Digestive and Kidney Diseases P30DK089507National Institutes of Health UL1TR000423NCATS NIH HHS UL1 TR002319NHLBI NIH HHS K23 HL138154NHLBI NIH HHS R01 HL103965NHLBI NIH HHS R01 HL113382NHLBI NIH HHS R01 HL124053NHLBI NIH HHS U01 HL114589NHLBI NIH HHS UM1 HL119073NIAID NIH HHS R01 AI101307NIDDK NIH HHS P30 DK089507Royal College of Physicians and Surgeons RCPSC16/DTF-08U.S. Food and Drug Administration R01FD003704
6 · The paper itselfAbstract
Comparative effectiveness research (CER) has become increasing central to clinical research in medicine. CER seeks to conduct clinical trials that compare different commonly used interventions in real-world settings (pragmatic clinical trials) and use a multitude of sources of evidence (including registries and cohort studies) to inform clinical decision making. CER also ensures that stakeholders (patients, families, care providers, insurers) have a voice in the research process by integrating formal stakeholder engagement as part of the research. This innovative approach to clinical research has distinct benefits and pitfalls. This review first defines what CER is and then describes some of its benefits and then pitfalls. The focus is on the role of CER in pediatrics.
Indexed as
AdolescentChildChild, PreschoolComparative Effectiveness ResearchHumansRespiratory Distress Syndrome
Identifiers
PMID28776129
PMCPMC5906049
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390